ABIVAX Announces Its Financial Calendar for 2018

PARIS--(BUSINESS WIRE)--

Regulatory News:

ABIVAX (Euronext Paris: FR0012333284 – ABVX) (Paris: ABVX), a biotechnology company harnessing the immune system to develop a functional cure for HIV and treatments for inflammatory/autoimmune diseases and cancer, today provides its planned financial calendar for 2018, which is set as follows:

Date*				Announcement
Friday March 16, 2018				Publication of 2017 Financial Statements
Monday April 30, 2018				Publication and Release of the 2017 Annual Financial Report
Friday June 15, 2018				Annual Shareholders Meeting
Monday September 19, 2018				Publication of Financial Statements as of June 30, 2018
Friday September 28, 2018				Publication and Release of 2018 Half Year Report

* Subject to modification. Press releases are distributed either before the financial markets opening, or after the closure

All corporate information on the Company, such as its financial statements or its corporate presentations, is available on the Company’s website in the Investors’ section (www.abivax.com/en).

About ABIVAX (www.abivax.com)

ABIVAX is an innovative biotechnology company targeting the immune system to develop novel treatments for viral and inflammatory diseases as well as cancer. ABIVAX leverages three technology platforms for drug discovery: an antiviral, an immune enhancement, and a polyclonal antibody platform. ABX464, its most advanced compound, is currently in Phase 2 clinical trials for providing a sustained viral remission or functional cure for patients with HIV/AIDS. It is a first-in-class oral small antiviral molecule which blocks HIV replication through a unique mechanism of action and also has a strong anti-inflammatory effect, which is currently explored through a phase 2a proof-of-concept clinical trial in ulcerative colitis. In addition, ABIVAX is advancing a clinical stage immune enhancer for the treatment of cancer as well as multiple preclinical candidates against additional viral targets (e.g., Respiratory Syncytial Virus (RSV), Influenza and Dengue), and several of these compounds are planned to enter clinical development within the next 18 months. ABIVAX is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX).More information on the company is available at www.abivax.com.

Follow us on Twitter @ABIVAX_

View source version on businesswire.com: http://www.businesswire.com/news/home/20171215005028/en/

ABIVAX
Finance
Didier Blondel, +33 1 53 83 08 41
[email protected]
or
Communication Agency
ALIZE RP
Caroline Carmagnol/Aurore Gangloff, +33 6 64 18 99 59 / +33 1 44 54 36 65
[email protected]
or
Investors
LifeSci Advisors
Chris Maggos, +41 79 367 6254
[email protected]
or
US Media
LifeSci Public Relations
Matt Middleman, M.D., +1 646 627 8384
[email protected]

Source: ABIVAX

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Onco-Innovations Enters into LOI with Ifowonco for Exclusive Option and Worldwide Licence to LAG-3 Small-Molecule Inhibitor Program
• MOBILE SUIT GUNDAM SEED FREEDOM ZERO Heads to New York Comic Con 2026 With Panel and Livestream
• Alchemy Labs Reports 17% Revenue Growth and 38.7% Gross Margin in Second Quarter 2026